Latest From NovellusDx
Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in July and August 2017.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Middle East
- Parent & Subsidiaries
- Senior Management
Haim Gil-Ad, CEO
Michael Vidne, PhD, Chief Commercial Officer
Gabi Tarcic, PhD, VP, R&D
- Contact Info
Jerusalem Bio-Park 5th Fl.
P.O. Box 12057 Jerusalem, 91120
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.